Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
URLC10, TTK, and KOC1 vaccine in refractory esophageal cancer
NCT00681330Phase 2Completed
- Sponsor
- The University of Tokyo
- Start
- May 2008
- Primary completion
- Apr 2009
- Modality
- Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of URLC10 in esophageal cancer, sponsored by The University of Tokyo. Primary endpoints: Safety and Tolerability at 2 months and Feasibility as evaluated by RECIST at 2 months. Started May 2008; status: completed.
02
Drugs
URLC10
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT00681330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00681330.